Serial Number: 09/773,598 Group Art Unit: 1646

AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

- 1-2. (Canceled)
- 3. (Previously presented): The method of Claim 4, wherein said porous cellulose carrier has an exclusion limit for globular protein of 5,000 to 600,000.
- 4. (Currently amended): A method for of treating a body fluid containing a transforming growth factor-β, comprising:

removing a the transforming growth factor-β from a the body fluid, which

wherein the step of removing the transforming growth factor-β comprises bringing a body fluid into contact with an adsorbent comprising (i) a porous cellulose carrier, and (ii) a compound immobilized on said carrier and having a log P value of at least 2.50 wherein P is a partition coefficient in an octanol-water system,

said body fluid being a member selected from the group consisting of plasma, serum, ascites, lymph and synovia.

- 5. (Canceled)
- 6. (New): The method of Claim 4, wherein the TGF- β is selectively adsorbed on the adsorbent.
- 7. (New): The method of Claim 4, wherein the body fluid is contacted with the adsorbent extracorporeally.

Serial Number: 09/773,598 Group Art Unit: 1646

8. (New): A method for removing a transforming growth factor- β from a body fluid, which comprises:

removing body fluid from a living body, wherein the body fluid is selected from the group consisting of plasma, serum, ascites, lymph and synovia,

bringing the body fluid into contact with an adsorbent comprising (i) a porous cellulose carrier, and (ii) a compound immobilized on said carrier and having a log P value of at least 2.50 wherein P is a partition coefficient in an octanol-water system, and

returning the body fluid to the living body.

9. (New): The method of claim 8, which is incorporated into an extracorporeal circulation circuit used in combination with another extracorporeal circulation therapy.